| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 11.23 | 73.8% | 26.9% |
| Total Income | 11.23 | 73.8% | 26.9% |
| Expenditure | 45.64 | 30.6% | 4.7% |
| PBT | -32.17 | 23.6% | 30.4% |
| Net Profit | -32.17 | 23.6% | 30.4% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.44 | 18.9% | 25.7% |
C4 Therapeutics Reports Q3 2025 Results
04 May 2026 · 4 May, 7:49 am
Summary
C4 Therapeutics, Inc. issued a press release on November 6, 2025, announcing its financial results and business highlights for the quarter ended September 30, 2025. The press release is furnished as an exhibit to the current report. The information is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Highlights
- 1
C4 Therapeutics, Inc. announced its financial results and business highlights for the quarter ended September 30, 2025.
- 2
The press release was issued on November 6, 2025.
- 3
The press release contains information about the company's financial results.
- 4
The press release contains information about the company's business highlights.
Informational and educational content only. Not investment advice.